Lineage Cell Therapeutics Inc
General ticker "LCTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $104.2M
Lineage Cell Therapeutics Inc does not follow the US Stock Market performance with the rate: -25.8%.
Estimated limits based on current volatility of 7.2%: low 0.48$, high 0.56$
Factors to consider:
- US accounted for 100.0% of revenue in the fiscal year ended 2022-12-31
- Current price 26.1% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.74$, 1.70$]
- 2024-12-30 to 2025-12-30 estimated range: [0.93$, 2.02$]
Financial Metrics affecting the LCTX estimates:
- Negative: Non-GAAP EPS, $ of -0.13 <= 0.10
- Negative: Operating profit margin, % of -73.44 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -14.11 <= 2.35
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term LCTX quotes
Long-term LCTX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $4.34MM | $14.70MM | $8.95MM |
| Operating Expenses | $53.55MM | $37.22MM | $33.68MM |
| Operating Income | $-49.21MM | $-22.52MM | $-24.73MM |
| Non-Operating Income | $5.94MM | $-3.29MM | $1.45MM |
| Interest Expense | $0.00MM | $5.18MM | $0.00MM |
| R&D Expense | $33.91MM | $13.99MM | $15.71MM |
| Income(Loss) | $-43.27MM | $-25.81MM | $-23.28MM |
| Taxes | $0.00MM | $0.54MM | $-1.80MM |
| Profit(Loss) | $-43.27MM | $-26.35MM | $-21.48MM |
| Stockholders Equity | $92.22MM | $73.34MM | $63.42MM |
| Inventory | $0.00MM | $0.00MM | $0.00MM |
| Assets | $174.54MM | $123.66MM | $101.02MM |
| Operating Cash Flow | $-23.56MM | $1.06MM | $-28.57MM |
| Capital expenditure | $0.35MM | $0.41MM | $0.67MM |
| Investing Cash Flow | $9.74MM | $-46.16MM | $46.45MM |
| Financing Cash Flow | $36.93MM | $1.63MM | $6.42MM |
| Earnings Per Share* | $-0.23 | $-0.16 | $-0.12 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.